When adults attempt to stop smoking using nicotine replacement therapy, e-cigarettes or other non-combustible nicotine products, one practical question quickly emerges: how much nicotine is enough?
The answer matters because cigarette dependence varies considerably between smokers. Two people who smoke the same number of cigarettes each day may not absorb the same amount of nicotine or experience the same level of dependence. Differences in smoking intensity, inhalation patterns and how quickly someone reaches for their first cigarette after waking can all provide additional information about nicotine dependence.
A questionnaire discussed recently by Professor Jean-François Etter of the University of Geneva attempts to capture these differences. Rather than estimating nicotine requirements from cigarettes per day alone, the approach combines five measures of smoking behaviour to estimate previous nicotine intake and inform nicotine substitution.
For GINN, the underlying principle raises a wider harm-reduction question. If smokers are encouraged to move away from combustible cigarettes, access to alternatives alone may not be sufficient. Those alternatives also need to provide a level of nicotine delivery that allows smokers to substitute cigarettes effectively.
Cigarettes Per Day Tell Only Part of the Story
Cigarette consumption is one of the simplest measures of smoking intensity. Someone smoking 20 cigarettes per day would generally be expected to have greater nicotine exposure than someone smoking only a few. But individual smoking behaviour complicates this relationship.
Smokers differ in the number and depth of puffs they take, how much smoke they inhale and how they smoke individual cigarettes. Dependence can also be reflected in behavioural measures. Time to first cigarette after waking, for example, has long been incorporated into established measures such as the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index.
The questionnaire presented by Etter expands the assessment beyond cigarette consumption. It considers five factors: cigarettes smoked per day, time between waking and the first cigarette, perceived smoking intensity, the amount of smoke inhaled each day and the nicotine yield indicated on the cigarette pack.
The resulting score is intended to provide an estimate of nicotine intake rather than relying on cigarette numbers alone. The broader principle is important: smokers with apparently similar consumption patterns may have different nicotine requirements when moving away from cigarettes.
Why Nicotine Adequacy Matters During Switching
Stopping smoking can produce withdrawal symptoms including cravings, irritability, anxiety, difficulty concentrating and changes in mood and appetite. Nicotine replacement products are intended partly to reduce these symptoms while separating nicotine intake from cigarette smoke.
If nicotine substitution is inadequate, an adult who has stopped smoking may continue to experience cravings or withdrawal. This can make complete substitution more difficult and may increase the likelihood of returning to cigarettes.
Evidence from nicotine-replacement research also shows why nicotine intake after switching cannot simply be inferred from the amount stated on a product label. Research measuring salivary cotinine, a biomarker of nicotine exposure, has found differences in nicotine intake between smokers and former smokers using nicotine replacement therapy.
The important point is therefore not that every smoker requires a high nicotine dose. It is that nicotine needs vary, and the appropriate level should be sufficient to control withdrawal without assuming that one concentration or product configuration will work for everyone.
Product Strength and Nicotine Delivery Are Not the Same Thing
This distinction becomes particularly important when moving between different nicotine products.
A cigarette, nicotine patch, gum, pouch and e-cigarette may all contain or deliver nicotine, but they do so in very different ways. The quantity contained in the product is not necessarily the quantity absorbed by the user.
For e-cigarettes, nicotine delivery can depend on the concentration of the liquid, device characteristics, formulation, puffing behaviour and user experience. Etter’s earlier research involving e-cigarette users has documented substantial variation in how these products are used, including differences in nicotine concentration and consumption patterns.
Nicotine pouches raise similar questions. The number of milligrams printed on a pouch describes nicotine content, but actual nicotine delivery can also be influenced by formulation and product characteristics. This is consistent with the wider evidence GINN has previously examined around nicotine concentration, pH and product performance.
For regulators, this means that labelled nicotine content and actual nicotine delivery should not automatically be treated as equivalent measures.
Underdosing Can Have Unintended Consequences
The video places particular emphasis on underdosing. Etter argues that former smokers using e-cigarettes may compensate for insufficient nicotine concentration by consuming more liquid, while inadequate nicotine replacement can leave withdrawal symptoms unresolved.
The underlying concept is behavioural compensation. If a product delivers less nicotine than an experienced smoker requires, the user may change how frequently or intensely the product is used in an attempt to obtain the desired effect.
This deserves attention in regulatory discussions about maximum nicotine concentrations. Limits are often introduced with the intention of reducing nicotine exposure or dependence. But a concentration limit does not necessarily translate directly into a corresponding reduction in nicotine intake. Consumer behaviour can change in response to product characteristics.
This does not mean nicotine-strength limits are inherently inappropriate. It means that their effects should be assessed using evidence about actual use rather than nicotine concentration alone.
Different Products May Require Different Approaches
The questionnaire also highlights why nicotine regulation cannot easily be reduced to a single universal strength standard.
Medicinal nicotine products are designed around controlled dosing and established therapeutic use. E-cigarettes involve a combination of liquid concentration, device performance and individual puffing behaviour. Nicotine pouches have their own formulation and release characteristics.
Each category therefore presents different questions about nicotine content, delivery and consumer behaviour.
A risk-proportionate regulatory framework should be capable of recognising those differences. Product standards may need to consider nicotine content alongside delivery characteristics, quality controls and evidence about how products are actually used.
This is particularly important where the objective is to support complete movement away from combustible cigarettes while limiting inappropriate uptake among young people and people who do not currently use nicotine.
What This Means for Harm Reduction
Smoking cessation remains the preferred outcome, and people who can stop using tobacco and nicotine entirely should be supported in doing so. But for smokers who use nicotine-containing alternatives to move away from cigarettes, the effectiveness and acceptability of those alternatives matter.
An alternative that does not adequately address nicotine withdrawal may be less capable of replacing smoking, even if it is technically available to the consumer.
This creates a difficult but important balance for regulators. Nicotine products should not deliver unnecessarily excessive amounts of nicotine, and safeguards are needed around youth access, product quality, labelling and responsible marketing. At the same time, regulation should recognise that adult smokers differ substantially in their dependence and nicotine requirements.
A single cigarette count, nicotine concentration or milligram limit cannot necessarily capture those differences.
Regulation Should Consider How Products Are Actually Used
The broader lesson from Etter’s approach is that nicotine substitution is more individual than simple cigarette-count calculations suggest.
Dependence, smoking behaviour, product formulation and nicotine delivery interact. Understanding these factors can help researchers and clinicians develop better approaches to smoking cessation, but they should also inform regulatory thinking.
For GINN, this reinforces the case for product standards grounded in real-world use and nicotine delivery rather than nicotine content alone. Regulators need to protect young people and non-users while ensuring that policies aimed at reducing nicotine exposure do not inadvertently make non-combustible alternatives less effective for adults attempting to leave cigarettes behind.
The policy question should therefore extend beyond asking how much nicotine a product contains. Regulators should also consider how much nicotine it delivers, how consumers respond to that delivery, and whether the product can adequately substitute for smoking among the adults who use it for that purpose.
Getting nicotine regulation right requires understanding not only the product, but the smoker who is trying to leave cigarettes behind.
Sources
Jean-François Etter, Jacques Le Houezec and Thomas V. Perneger, A Self-Administered Questionnaire to Measure Dependence on Cigarettes: The Cigarette Dependence Scale, Neuropsychopharmacology (2003).
